Nurix Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Nurix Therapeutics CEO'su Arthur Sands, Sep2014 tarihinde atandı, in görev süresi 10.17 yıldır. in toplam yıllık tazminatı $ 4.36M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13.5% maaş ve 86.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.44% ine doğrudan sahiptir ve bu hisseler $ 7.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.4 yıl ve 4.2 yıldır.

Anahtar bilgiler

Arthur Sands

İcra Kurulu Başkanı

US$4.4m

Toplam tazminat

CEO maaş yüzdesi	13.5%
CEO görev süresi	10.2yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	4.4yrs
Yönetim Kurulu ortalama görev süresi	4.2yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

CEO Tazminat Analizi

Arthur Sands'un ücretlendirmesi Nurix Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Aug 31 2024	n/a	n/a	-US$177m
May 31 2024	n/a	n/a	-US$165m
Feb 29 2024	n/a	n/a	-US$145m
Nov 30 2023	US$4m	US$591k	-US$144m
Aug 31 2023	n/a	n/a	-US$149m
May 31 2023	n/a	n/a	-US$157m
Feb 28 2023	n/a	n/a	-US$179m
Nov 30 2022	US$9m	US$572k	-US$180m
Aug 31 2022	n/a	n/a	-US$171m
May 31 2022	n/a	n/a	-US$154m
Feb 28 2022	n/a	n/a	-US$135m
Nov 30 2021	US$5m	US$539k	-US$117m
Aug 31 2021	n/a	n/a	-US$99m
May 31 2021	n/a	n/a	-US$89m
Feb 28 2021	n/a	n/a	-US$63m
Nov 30 2020	US$17m	US$521k	-US$43m
Aug 31 2020	n/a	n/a	-US$37m
May 31 2020	n/a	n/a	-US$21m
Feb 29 2020	n/a	n/a	-US$24m
Nov 30 2019	US$1m	US$474k	-US$22m

Tazminat ve Piyasa: Arthur 'ın toplam tazminatı ($USD 4.36M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.64M ).

Tazminat ve Kazançlar: Arthur 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Arthur Sands (62 yo)

10.2yrs

Görev süresi

US$4,363,120

Tazminat

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arthur Sands	CEO, President & Director	10.2yrs	US$4.36m	0.44% $ 7.7m
Johannes Van Houte	Chief Financial Officer	8.7yrs	US$1.61m	0.048% $ 844.5k
Gwenn Hansen	Chief Scientific Officer	4.4yrs	US$1.63m	0.072% $ 1.3m
John Kuriyan	Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Rapé	Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Arthur Weiss	Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Rita Kwong	Senior Accounting Manager	no data	Veri yok	Veri yok
Pasit Phiasivongsa	Chief Technical Officer	less than a year	Veri yok	Veri yok
Christine Ring	Chief Legal Officer	5.2yrs	US$1.65m	0.040% $ 703.3k
Eric Schlezinger	Chief People Officer	2.3yrs	Veri yok	Veri yok
Jason Kantor	Chief Business Officer	4.3yrs	Veri yok	Veri yok
Christopher Phelps	Senior VP & Head of Early Drug Discovery	3.8yrs	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: NRIX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Arthur Sands	CEO, President & Director	10.2yrs	US$4.36m	0.44% $ 7.7m
John Kuriyan	Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Rapé	Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Arthur Weiss	Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Julia Gregory	Independent Chairman	5.3yrs	US$238.29k	0% $ 0
Ronald Levy	Member of Medical Advisory Board	1.8yrs	Veri yok	Veri yok
Judith Reinsdorf	Independent Director	3.1yrs	US$225.79k	0% $ 0
Roy Baynes	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Lori Kunkel	Independent Director	5.3yrs	US$228.29k	0% $ 0
David Lacey	Independent Director	8.6yrs	US$263.29k	0.047% $ 834.7k
Paul Silva	Independent Director	3.1yrs	US$225.79k	0% $ 0
Edward Saltzman	Independent Director	2.2yrs	US$223.29k	0% $ 0

4.2yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NRIX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).

Nurix Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Recent updates

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix Therapeutics, Inc. Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors

Nurix: An Attractive Early-Stage Biotech Play

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Price target decreased to US$38.20

Price target decreased to US$38.80

Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million.

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Nurix Therapeutics, Inc. Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Nurix Therapeutics, Inc.(NasdaqGM:NRIX) dropped from Russell 2000 Growth Index

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs At the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Chief Financial Officer exercised options to buy US$621k worth of stock.

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

Nurix Therapeutics, Inc. Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948

High number of new directors